Risk Factors for Persistent Staphylococcus aureus Bacteremia in Children.

Pediatr Infect Dis J

From the Division of Critical Care Medicine, Nationwide Children's Hospital, Columbus, OH.

Published: November 2024

Background: Staphylococcus aureus is a leading cause of pediatric bacteremia. Persistent S. aureus bacteremia (SAB) is associated with increased morbidity and mortality in adults and children. Risk factors for S. aureus bacteremia have been well established, but there is a limited understanding of the factors that contribute to the development of persistent SAB in children.

Methods: This is a single-center retrospective secondary analysis of a prospective observational study of pediatric patients hospitalized with S. aureus infection over a 3.5-year period at a large, quaternary, children's hospital.

Results: Two hundred fifty-nine children with confirmed S. aureus infection were enrolled in the study. Sixty-five of these were found to have bacteremia, with 28 (43%) developing persistent bacteremia. Patients with persistent SAB were culture-positive for a median of 3.5 days compared with 1 day for those without ( P ≤ 0.001). Children with persistent SAB were more likely to have an identified osteoarticular source of infection (93%, n = 26 vs. 62%, n = 23; P = 0.008) and had a shorter median duration to culture positivity than those without persistent SAB (16 hours vs. 20 hours; P ≤ 0.001). In addition, children with persistent SAB had higher median values of presenting erythrocyte sedimentation rate, peak erythrocyte sedimentation rate, presenting C-reactive protein and peak C-reactive protein. Not surprisingly, hospital length of stay was longer in children with persistent SAB compared with those without.

Conclusions: These findings suggest that a shorter time to culture positivity, osteoarticular infection, and higher presenting and peak values for select inflammatory markers are potential risk factors for persistent SAB in children.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11662081PMC
http://dx.doi.org/10.1097/INF.0000000000004439DOI Listing

Publication Analysis

Top Keywords

persistent sab
28
risk factors
12
aureus bacteremia
12
children persistent
12
persistent
10
factors persistent
8
staphylococcus aureus
8
sab
8
aureus infection
8
≤ 0001
8

Similar Publications

Point of view: Challenges in implementation of new immunotherapies for Alzheimer's disease.

J Prev Alzheimers Dis

January 2025

Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, BioClinicum, 171 64 Solna, Sweden; Theme Inflammation and Aging, Karolinska University Hospital, 141 86 Stockholm, Sweden.

The advancement of disease-modifying treatments (DMTs) for Alzheimer's disease (AD), along with the approval of three amyloid-targeting therapies in the US and several other countries, represents a significant development in the treatment landscape, offering new hope for addressing this once untreatable chronic progressive disease. However, significant challenges persist that could impede the successful integration of this class of drugs into clinical practice. These challenges include determining patient eligibility, appropriate use of diagnostic tools and genetic testing in patient care pathways, effective detection and monitoring of side effects, and improving the healthcare system's readiness by engaging both primary care and dementia specialists.

View Article and Find Full Text PDF

Case: An 18-year-old woman presented with shoulder pain that had persisted for a year. The magnetic resonance imaging showed a solitary lesion in the subacromial bursa (SAB). Arthroscopy revealed an ovoid mass connected to the bursal wall with thin synovial tissue that was excised en bloc arthroscopically.

View Article and Find Full Text PDF

Chimeric antigen receptor T cells (CAR T cells) with T stem (T) cell-like phenotypic characteristics promote sustained antitumor effects. We performed an unbiased and automated high-throughput screen of a kinase-focused compound set to identify kinase inhibitors (KIs) that preserve human T cell-like CAR T cells. We identified three KIs, UNC10225387B, UNC10225263A and UNC10112761A, that combined in vitro increased the frequency of CD45RACCR7TCF1 T cell-like CAR T cells from both healthy donors and patients with cancer.

View Article and Find Full Text PDF

Risk Factors for Infection-Attributable Mortality in Patients With Bacteremia: A Competing Risk Analysis.

Open Forum Infect Dis

January 2025

Division of Infectious Diseases, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.

Background: Identifying risk factors for mortality in patients with bacteremia (SAB) is crucial due to its high fatality. However, data on risk factors for infection-attributable deaths considering competing risk events such as non-infection-attributable deaths remain limited. We performed a competing risk analysis to elucidate risk factors associated with 30-day infection-attributable mortality in a large cohort of patients with SAB.

View Article and Find Full Text PDF

Smart Cell Therapy: an industry perspective on macrophages as living drugs.

Cytotherapy

December 2024

Barcia Novel Therapies, Lexington, Massachusetts, USA. Electronic address:

Macrophage-based cell therapies represent a cutting-edge frontier in immunotherapy, offering distinct advantages over conventional approaches like CAR-T. This review explores the potential of macrophages to orchestrate both innate and adaptive immune responses, enhancing the body's ability to combat diseases locally and systemically. Dubbed a "Smart Cell Therapy," macrophages can initiate and coordinate complex immunological cascades, leveraging multiple immune system components while also performing effector functions.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!